To view this email as a web page, click here

Today's Rundown

Featured Story

'Unsurprising' but 'deeply disappointing': Deerfield report finds vast gender gap in VC-backed healthcare

Studies on diversity in the life sciences industry often look at the makeup of companies’ employees, executive teams and board members. In a new report, Deerfield Management zeroed in on early-stage companies and the venture capital firms that back them, offering a look at gender diversity in company creation.

read more

Top Stories

Volastra bumps up seed round to $44M, inks Microsoft partnership to tackle cancer metastasis

Metastatic cancer is responsible for most cancer deaths, but people whose disease has spread to other parts of the body don’t have enough effective treatment options. Volastra Therapeutics wants to change that by developing drugs that target chromosomal instability, a hallmark of solid tumors that’s linked to metastasis.

read more

The top 10 pharma R&D budgets in 2020

While 2020 was a year to forget for almost the entire globe, the R&D engine of pharma roared to life in a never-before-seen way by creating new drugs, vaccines and tests for the pandemic that ravaged the world.

read more

Sponsored: NAFLD & NASH: Emerging In Vitro Models Aid Drug Discovery

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common pathologies without specialized therapeutics, but new models may provide opportunities for drug discovery.

read more

Novavax adds blinded crossover arms to COVID-19 vaccine trials

Novavax has added crossover arms to late-phase clinical trials of its COVID-19 vaccine. The action will enable participants in the placebo cohorts of the original trials to get vaccinated without unblinding the studies.

read more

Scholar Rock eyes phase 3 after confirming effects of SMA drug

Scholar Rock has reported 12-month data on spinal muscular atrophy candidate apitegromab. The readout is in line with the six-month data drop that sent Scholar Rock’s stock price soaring in October, teeing the biotech up to move into a pivotal study by the end of the year. 

read more

Invitae's double deal day: A genomics buyout and $1.2B in SoftBank-led financing

It's been a busy day for Invitae. The genetic testing provider inked a $200 million buyout and wrapped up a hefty investment from a group of backers marshaled by SoftBank.

read more

Resources

Whitepaper: COVID-19 Survey report: The Lasting Impact on Outsourcing Decisions

How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond?

Content Hub: Emerging Biotech Resource Center

A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule

Whitepaper: Top 5 Benefits of a Cloud ELN

Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes.

Annual Report: Why do US pharma come to Russia for clinical trials.

Find out why more than 400 clinical trials annually are initiated in Russia by US and EU pharma in the free annual report by OCT Clinical.

Special Report: The Marketer’s Guide to Taking the Vaccine Viral

Access this guide for the latest insights into how marketers can use data, technology, and personalized messaging to build vaccine confidence and drive successful immunization efforts.

Content Hub: How to improve the virtual work you do every day

We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Whitepaper: Roche to pick up GenMark Diagnostics in $1.8B infectious disease testing deal

Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously.

Report: State of the Industry Report: Embracing Trial Change and Elevating IRT Systems

This industry report reveals qualitative and quantitative candid insight from clinical development insiders and their views on current clinical trial challenges faced amidst uncertainty.

Content Hub: Remarque Systems Resource Hub

Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. 

Whitepaper: New Data: A Better Way to Run CHO Cell Culture Experiments

Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly.

Whitepaper: Overcoming the hurdles of Real-World Data Access through a federated global network

Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Executive Summary: Manufacturing Strategies to Effectively Industrialize Autologous Cell Therapies

Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Whitepaper: Achieving a Successful Drug Product Technology Transfer

Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent.

Whitepaper: The Art of Recognizing Clinical Supply Risk Factors

In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management.

eBook: Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

Events